Last updated: 21 June 2021 at 5:06pm EST

Gerald Cagle Net Worth




The estimated Net Worth of Gerald D. Cagle is at least $658 Thousand dollars as of 8 May 2020. Gerald Cagle owns over 5,000 units of Aerie Pharmaceuticals Inc stock worth over $252,388 and over the last 10 years he sold AERI stock worth over $76,378. In addition, he makes $329,246 as Independent Director at Aerie Pharmaceuticals Inc.

Gerald Cagle AERI stock SEC Form 4 insiders trading

Gerald has made over 16 trades of the Aerie Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of AERI stock worth $76,350 on 8 May 2020.

The largest trade he's ever made was exercising 45,454 units of Aerie Pharmaceuticals Inc stock on 11 May 2018 worth over $18,182. On average, Gerald trades about 3,444 units every 70 days since 2014. As of 8 May 2020 he still owns at least 16,550 units of Aerie Pharmaceuticals Inc stock.

You can see the complete history of Gerald Cagle stock trades at the bottom of the page.





Gerald Cagle biography

Dr. Gerald D. Cagle Ph.D. serves as Independent Director of the Company. Dr. Cagle was appointed Senior Vice President of Research & Development at Alcon Laboratories Inc. in 1997, a position he held until 2009. From 2009 until his retirement in 2013, Dr. Cagle held the position of Chief Operating Officer at Cognoptix, a company focused on the diagnosis of Alzheimer's disease. Dr. Cagle also serves on the board of directors of GrayBug, Inc., Nacuity, Pharmaceuticals, Inc., and AB2 Bio Ltd. Dr. Cagle received his B.S. from Wayland College, earned both his M.S. and Ph.D. from the University of North Texas and completed the Program for Management Development at Harvard Business School.

What is the salary of Gerald Cagle?

As the Independent Director of Aerie Pharmaceuticals Inc, the total compensation of Gerald Cagle at Aerie Pharmaceuticals Inc is $329,246. There are 11 executives at Aerie Pharmaceuticals Inc getting paid more, with Vicente Anido having the highest compensation of $5,529,670.



How old is Gerald Cagle?

Gerald Cagle is 75, he's been the Independent Director of Aerie Pharmaceuticals Inc since 2013. There are no older and 21 younger executives at Aerie Pharmaceuticals Inc.

What's Gerald Cagle's mailing address?

Gerald's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM, NC, 27703.

Insiders trading at Aerie Pharmaceuticals Inc

Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra, and Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.



What does Aerie Pharmaceuticals Inc do?

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.



What does Aerie Pharmaceuticals Inc's logo look like?

Aerie Pharmaceuticals Inc logo

Complete history of Gerald Cagle stock trades at Aerie Pharmaceuticals Inc, Clearside Biomedical Inc, and Graybug Vision

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
8 May 2020 Gerald D. Cagle
Director
Sale 5,000 $15.27 $76,350
8 May 2020
16,550
16 Nov 2018 Gerald D. Cagle
Director
Buy 2,000 $41.75 $83,500
16 Nov 2018
19,800
25 May 2018 Gerald D. Cagle
Director
Buy 1,000 $49.45 $49,450
25 May 2018
16,050
21 May 2018 Gerald D. Cagle
Director
Buy 1,000 $50.25 $50,250
21 May 2018
15,050
9 May 2017 Gerald D. Cagle
Director
Buy 1,000 $39.90 $39,900
9 May 2017
12,900
19 Apr 2017 Gerald D. Cagle
Director
Buy 2,000 $41.70 $83,400
19 Apr 2017
11,900
4 Feb 2015 Gerald D. Cagle
Director
Buy 4,646 $18.24 $84,743
4 Feb 2015
8,200
16 May 2014 Gerald D. Cagle
Director
Buy 1,854 $15.07 $27,940
16 May 2014
1,854
25 Jun 2018 Gerald D. Cagle
Director
Option 11,250 $8.88 $99,900
25 Jun 2018
80,145
11 May 2018 Gerald D. Cagle
Director
Option 45,454 $0.40 $18,182
11 May 2018
68,895
22 Mar 2018 Gerald D. Cagle
Director
Buy 7,500 $11.89 $89,175
22 Mar 2018
23,441
11 Aug 2017 Gerald D. Cagle
Director
Buy 5,000 $7.08 $35,400
11 Aug 2017
15,941
27 Mar 2017 Gerald D. Cagle
Director
Buy 14,064 $7.10 $99,854
27 Mar 2017
14,064
16 Mar 2017 Gerald D. Cagle
Director
Buy 5,000 $6.84 $34,200
16 Mar 2017
10,941
7 Jun 2016 Gerald D. Cagle
Director
Sale 2 $7.00 $14
7 Jun 2016
5,941
7 Jun 2016 Gerald D. Cagle
Director
Sale 2 $7.00 $14
7 Jun 2016
5,941


Aerie Pharmaceuticals Inc executives and stock owners

Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include: